A Single and Multiple Ascending Dose Study of LY3876602 in Healthy Participants

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

August 23, 2023

Primary Completion Date

September 20, 2025

Study Completion Date

September 20, 2025

Conditions

Healthy

Interventions

DRUG

LY3876602

Administered IV.

DRUG

Placebo

Administered IV.

Trial Locations (1)

ICON Early Phase Services, LLC, Groningen

All Listed Sponsors

lead

Eli Lilly and Company

INDUSTRY

NCT06007638 - A Single and Multiple Ascending Dose Study of LY3876602 in Healthy Participants | Biotech Hunter | Biotech Hunter